Cargando…

EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies

INTRODUCTION: In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute exacerbation of COPD (AECOPD), compared with a non-exacerbation period. While the effect of severe AECOPD is w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordon, Clementine, Rhodes, Kirsty, Quint, Jennifer K, Vogelmeier, Claus F, Simons, Sami O, Hawkins, Nathaniel M, Marshall, Jonathan, Ouwens, Mario, Garbe, Edeltraut, Müllerová, Hana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151875/
https://www.ncbi.nlm.nih.gov/pubmed/37185641
http://dx.doi.org/10.1136/bmjopen-2022-070022
_version_ 1785035635756630016
author Nordon, Clementine
Rhodes, Kirsty
Quint, Jennifer K
Vogelmeier, Claus F
Simons, Sami O
Hawkins, Nathaniel M
Marshall, Jonathan
Ouwens, Mario
Garbe, Edeltraut
Müllerová, Hana
author_facet Nordon, Clementine
Rhodes, Kirsty
Quint, Jennifer K
Vogelmeier, Claus F
Simons, Sami O
Hawkins, Nathaniel M
Marshall, Jonathan
Ouwens, Mario
Garbe, Edeltraut
Müllerová, Hana
author_sort Nordon, Clementine
collection PubMed
description INTRODUCTION: In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute exacerbation of COPD (AECOPD), compared with a non-exacerbation period. While the effect of severe AECOPD is well established, the relationship of moderate exacerbation or prior exacerbation to elevated risk of CV events is less clear. We will conduct cohort studies in multiple countries to further characterise the association between AECOPD and CV events. METHODS AND ANALYSIS: Retrospective longitudinal cohort studies will be conducted within routinely collected electronic healthcare records or claims databases. The study cohorts will include patients meeting inclusion criteria for COPD between 1 January 2014 and 31 December 2018. Moderate exacerbation is defined as an outpatient visit and/or medication dispensation/prescription for exacerbation; severe exacerbation is defined as hospitalisation for COPD. The primary outcomes of interest are the time to (1) first hospitalisation for a CV event (including acute coronary syndrome, heart failure, arrhythmias or cerebral ischaemia) since cohort entry or (2) death. Time-dependent Cox proportional hazards models will compare the hazard of a CV event between exposed periods following exacerbation (split into these periods: 1–7, 8–14, 15–30, 31–180 and 181–365 days) and the unexposed reference time period, adjusted on time-fixed and time-varying confounders. ETHICS AND DISSEMINATION: Studies have been approved in Canada, Japan, the Netherlands, Spain and the UK, where an institutional review board is mandated. For each study, the results will be published in peer-reviewed journals.
format Online
Article
Text
id pubmed-10151875
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101518752023-05-03 EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies Nordon, Clementine Rhodes, Kirsty Quint, Jennifer K Vogelmeier, Claus F Simons, Sami O Hawkins, Nathaniel M Marshall, Jonathan Ouwens, Mario Garbe, Edeltraut Müllerová, Hana BMJ Open Respiratory Medicine INTRODUCTION: In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute exacerbation of COPD (AECOPD), compared with a non-exacerbation period. While the effect of severe AECOPD is well established, the relationship of moderate exacerbation or prior exacerbation to elevated risk of CV events is less clear. We will conduct cohort studies in multiple countries to further characterise the association between AECOPD and CV events. METHODS AND ANALYSIS: Retrospective longitudinal cohort studies will be conducted within routinely collected electronic healthcare records or claims databases. The study cohorts will include patients meeting inclusion criteria for COPD between 1 January 2014 and 31 December 2018. Moderate exacerbation is defined as an outpatient visit and/or medication dispensation/prescription for exacerbation; severe exacerbation is defined as hospitalisation for COPD. The primary outcomes of interest are the time to (1) first hospitalisation for a CV event (including acute coronary syndrome, heart failure, arrhythmias or cerebral ischaemia) since cohort entry or (2) death. Time-dependent Cox proportional hazards models will compare the hazard of a CV event between exposed periods following exacerbation (split into these periods: 1–7, 8–14, 15–30, 31–180 and 181–365 days) and the unexposed reference time period, adjusted on time-fixed and time-varying confounders. ETHICS AND DISSEMINATION: Studies have been approved in Canada, Japan, the Netherlands, Spain and the UK, where an institutional review board is mandated. For each study, the results will be published in peer-reviewed journals. BMJ Publishing Group 2023-04-26 /pmc/articles/PMC10151875/ /pubmed/37185641 http://dx.doi.org/10.1136/bmjopen-2022-070022 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Respiratory Medicine
Nordon, Clementine
Rhodes, Kirsty
Quint, Jennifer K
Vogelmeier, Claus F
Simons, Sami O
Hawkins, Nathaniel M
Marshall, Jonathan
Ouwens, Mario
Garbe, Edeltraut
Müllerová, Hana
EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies
title EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies
title_full EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies
title_fullStr EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies
title_full_unstemmed EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies
title_short EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies
title_sort exacerbations of copd and their outcomes on cardiovascular diseases (exacos-cv) programme: protocol of multicountry observational cohort studies
topic Respiratory Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151875/
https://www.ncbi.nlm.nih.gov/pubmed/37185641
http://dx.doi.org/10.1136/bmjopen-2022-070022
work_keys_str_mv AT nordonclementine exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT rhodeskirsty exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT quintjenniferk exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT vogelmeierclausf exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT simonssamio exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT hawkinsnathanielm exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT marshalljonathan exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT ouwensmario exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT garbeedeltraut exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies
AT mullerovahana exacerbationsofcopdandtheiroutcomesoncardiovasculardiseasesexacoscvprogrammeprotocolofmulticountryobservationalcohortstudies